What is Opus Genetics's long-term debt?

Opus Genetics (IRD) reported long-term debt of $1.2M in Q1 2026.

What does long-term debt mean?

Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Opus Genetics IRD Long-Term Debt

Long-Term Debt at other companies

MeiraGTx Holdings plcMGTX

$49.7M-32.4%

Regeneron PharmaceuticalsREGN

$1.99B+0.1%

Candel Therapeutics, Inc.CADL

$1.05M+15.8%

uniQureQURE

$49.94M-3.2%

PrecigenPGEN

$93.52M—

Taysha Gene Therapies, Inc.TSHA

$48.96M+15.3%

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's long-term debt?: Opus Genetics (IRD) reported long-term debt of $1.2M in Q1 2026.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.